Clinical trial NCT03565835: Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Official title: Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Prostatic Neoplasms
Keywords: abiraterone
prostate cancer
androgen deprivation therapy
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2018-06-21
Enrollment: 32
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out if testosterone in the blood will stay low while abiraterone and prednisone are used without continued hormone injections.

Detailed description: Abiraterone inhibits the CYP17A enzyme, which is a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in metastatic castration-resistant prostate cancer (mCRPC) in both chemotherapy-naïve and in the post-docetaxel setting based upon results from two randomized phase III studies. Abiraterone is also proven to extend survival in the metastatic, hormone-naïve population based on two phase III studies. Abiraterone is a castrating agent, but, other than a small first in human study, all clinical studies have been done in conjunction with gonadotropin-releasing hormone (GnRH) analogues. Maintaining castrate level of serum testosterone is critical in the treatment of metastatic prostate cancer. It is unknown if GnRH analogues must be continued to maintain castrate levels of serum testosterone in patients treated with abiraterone.

Eligibility criteria: Inclusion Criteria:

1. The patient must be able to provide study-specific informed consent prior to study entry
2. Age ≥ 18
3. ECOG (Eastern Cooperative Oncology Group) Performance Status 0-2
4. Pathologically proven diagnosis of prostate adenocarcinoma
5. Patients must have metastatic prostate cancer
6. Patients may have mCRPC or may have metastatic castration-sensitive disease.
7. Patients must be maintained on a GnRH analogue (agonist (leuprolide, goserelin, triptorelin, histrelin, deslorelin) or antagonist (degarelix))
8. The patient and the investigator have decided that the next line of cancer therapy will be abiraterone plus prednisone and the initial dose of abiraterone will be 1000 mg daily. Or patients may already be on abiraterone with prednisone at a dose of 1000 mg daily along with a GnRH analogue.
9. Lab values meeting the following criteria

   1. Total testosterone level of \<50 ng/dl
   2. Total bilirubin \< 2.0 X Upper Limit of Normal (ULN)
   3. Aspartate aminotransferase (AST) ≤ 3 X ULN
   4. Alanine aminotransferase (ALT ) ≤ 3 X ULN
   5. Absolute Neutrophil Count \> 1.5 K/mm3
   6. Platelets \> 100 K/mm3
   7. Hemoglobin ≥9.0 g/dL
   8. calculated creatinine clearance ≥ 30 mL/min

   Exclusion Criteria:
10. History of bilateral orchiectomy
11. History of hypopituitarism
12. For patient not yet started on abiraterone with prednisone, uncontrolled hypertension (systolic blood pressure \>170 mm Hg or diastolic blood pressure \>100 mm Hg)
13. Patients must not have New York Heart Association Class III or IV heart failure at the time of screening. Patients must not have any unstable angina, myocardial infarction, or serious uncontrolled cardiac arrhythmia within 6 months prior to registration
14. Any other serious illness or medical condition that the principal investigator feels would make the patient a poor candidate for this study

Primary outcomes:
measure: Proportion of patients with a non-castrate (>50 ng/dl) serum testosterone
timeFrame: 24 weeks
Secondary outcomes:
measure: Luteinizing hormone (LH) level after discontinuation of GnRH analogue
timeFrame: 24 weeks
measure: PSA (Prostate-specific antigen) response rate
timeFrame: 24 weeks
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
timeFrame: 24 weeks
measure: Radiographic progression-free survival (rPFS)
timeFrame: 24 weeks
measure: Median overall survival
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Benjamin Gartrell, MD
role: PRINCIPAL_INVESTIGATOR
References: